Intra-Cellular Therapies/ITCI

$73.94

-0.8%
-
1D1W1MYTD1YMAX

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Ticker

ITCI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sharon Mates

Employees

610

Headquarters

New york, United States

ITCI Metrics

BasicAdvanced
$7.01B
Market cap
-
P/E ratio
-$1.46
EPS
0.99
Beta
-
Dividend rate
$7.01B
0.99489
$84.89
$45.50
947.04K
5.405
5.311
-18.84%
-22.39%
-21.89%
15.087
11.794
11.846
85.51%
46.55%
173.04%

What the Analysts think about ITCI

Analyst Ratings

Majority rating from 17 analysts.
Buy

Price Targets

Average projection from 15 analysts.
24.3% upside
High $120.00
Low $65.00
$73.94
Current price
$91.91
Average price target

ITCI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-21.59% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$132M
4.68%
Net income
$-28.5M
17.77%
Profit margin
-21.59%
12.51%

ITCI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 32.23%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.46
-$0.45
-$0.25
-$0.30
-
Expected
-$0.61
-$0.59
-$0.57
-$0.44
-$0.33
Surprise
-24.11%
-23.75%
-55.83%
-32.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Intra-Cellular Therapies stock?

Intra-Cellular Therapies (ITCI) has a market cap of $7.01B as of April 23, 2024.

What is the P/E ratio for Intra-Cellular Therapies stock?

The price to earnings (P/E) ratio for Intra-Cellular Therapies (ITCI) stock is 0 as of April 23, 2024.

Does Intra-Cellular Therapies stock pay dividends?

No, Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Intra-Cellular Therapies dividend payment date?

Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders.

What is the beta indicator for Intra-Cellular Therapies?

Intra-Cellular Therapies (ITCI) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Intra-Cellular Therapies stock price target?

The target price for Intra-Cellular Therapies (ITCI) stock is $91.91, which is 24.3% above the current price of $73.94. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Intra-Cellular Therapies stock

Buy or sell Intra-Cellular Therapies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing